CLINICAL TRIALS PROFILE FOR KAE609
✉ Email this page to a colleague
Clinical Trials for KAE609
Trial ID | Title | Status | Sponsor | Phase | Summary |
---|---|---|---|---|---|
NCT01524341 ↗ | Efficacy, Safety, Tolerability and Pharmacokinetics of KAE609 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-infection | Completed | Novartis Pharmaceuticals | Phase 2 | This study will assess efficacy, safety , tolerability and PK in uncomplicated adult malaria patients with P. vivax or P. falciparum infection after 3 day dosing with KAE609 at 30 mg/day |
NCT01836458 ↗ | A Study to Find the Minimum Inhibitory Concentration of KAE609 in Adult Male Patients With P. Falciparum Monoinfection | Completed | Novartis Pharmaceuticals | Phase 2 | This study aims to determine the Minimum Inhibitory Concentration of KAE609 in adult male patients with acute, uncomplicated malaria due to P.falciparum monoinfection after single dosing with KAE609 |
NCT01860989 ↗ | A Study to Assess Efficacy, Safety of KAE609 in Adult Patients With Acute Malaria Mono-infection | Completed | Novartis Pharmaceuticals | Phase 2 | This study will assess efficacy, safety , tolerability and PK in uncomplicated adult malaria patients with acute P. falciparum infection after single dose with KAE609 at 75 mg, 150mg, 225mg and 300mg/day |
NCT02543086 ↗ | Effectiveness of KAE609 in Reducing Asexual & Sexual Blood-stage P.Falciparum Infection & Infectivity to Mosquitos | Terminated | Medicine for Malaria Venture | Phase 1 | This is a single-center open label study conducted in multiple sequential cohorts using Induced Blood Stage Malaria infection in healthy volunteers to characterize the effectiveness of KAE609 against sexual and asexual blood stage forms of Plasmodium falciparum. This study is divided in 2 parts (Part A and part B). A total of 8 healthy volunteers per cohort will be enrolled. Based on the results of Part A, Part B will be undertaken to evaluate the effect of KAE609 following pretreatment with Piperaquine on sexual stage/gametocytemia and its activity as an inhibitor of onward transmission to mosquito vectors using experimental mosquito feeding assays. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for KAE609
Condition Name
Clinical Trial Locations for KAE609
Clinical Trial Progress for KAE609
Clinical Trial Phase
Clinical Trial Sponsors for KAE609
Sponsor Name